Proteros Joint Venture Rodin signs financing, research and option agreement with Biogen and Atlas Venture

Proteros Joint Venture Rodin signs financing, research and option agreement with Biogen and Atlas Venture

We are pleased to inform you about an important achievement of our Joint Venture, Rodin Therapeutics Inc., which Proteros co-founded in 2013 with Atlas Venture. In an agreement with Biogen and Atlas Venture the companies committed to a financing of US $17 million and a multi year research collaboration to develop novel therapeutics for neurological disorders. Biogen secured the option to acquire Rodin for up to US $485 million including total upfront and milestone payments.

For more details please follow the link below:

www.businesswire.com/news/home/20160106005434/en/Rodin-Announces-Equity-Financing-Collaboration-Biogen